Consolidated Statements of Comprehensive Loss-Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues:
Net product revenue	$ 0	$ 8,985	$ 0	$ 16,862
Collaborative agreements	0	25	0	33
Royalties and other revenue	234	153	261	267
Total revenues	234	9,163	261	17,162
Operating expenses:
Cost of sales (including finite-lived intangible asset amortization)	0	728	0	1,296
Research and development, including stock-based compensation of $1,184, $1,949, $2,470 and $4,125, respectively	10,257	57,301	22,866	112,482
Selling, general and administrative, including stock-based compensation of $1,602, $2,309, $3,167 and $4,565, respectively	7,936	14,113	16,193	28,801
Asset Impairment Charges	0	1,600	0	1,600
Total operating expenses	18,193	73,742	39,059	144,179
Loss from operations	(17,959)	(64,579)	(38,798)	(127,017)
Interest expense	(169)	(5,125)	(336)	(10,256)
Interest and other income, net	61	633	109	1,591
Net loss	$ (18,067)	$ (69,071)	$ (39,025)	$ (135,682)
Net income (loss) per common share, Basic	$ (0.13)	$ (0.65)	$ (0.27)	$ (1.27)
Shares used in computing net loss per common share, Basic	144,451	107,073	143,917	106,804
Unrealized gain on investments	$ (10)	$ (548)	$ 1	$ 228
Comprehensive loss	(18,077)	(69,619)	(39,024)	(135,454)
Supplemental Income Statement Elements [Abstract]
Stock-based compensation expense associated with selling, general and administrative expense	1,602	2,309	3,167	4,565
Stock-based compensation expense associated with research and development expense	$ 1,184	$ 1,949	$ 2,470	$ 4,125